Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic™'s expertise in iPSC cell therapy platform development and scale-up